Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Immatics US Inc. is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 4 actions are assigned to 4 distinct examiners, which indicates that each case is receiving an independent evaluation. This spread across 4 examiners suggests that the company's success is not tied to the specific tendencies of a single individual.
The prosecution effort spans 3 distinct art units, showing a moderate level of technical diversity for the 4 pending office actions. Because there are 3 art units for 4 actions, at least 1 art unit is handling multiple cases for the company. This concentration in 3 units allows for a more focused legal strategy compared to a portfolio spread across a larger number of administrative groups.
AMICK, THOMAS RUSSE is the busiest examiner for the company, with 1 pending office action currently on their docket. This 1 action is 1 of the 4 total pending office actions, demonstrating that the workload is evenly distributed among the 4 distinct examiners. The combination of 4 examiners and 3 art units provides a balanced prosecution environment for the company's biotechnology applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AMICK, THOMAS RUSSE | 1 | 73.8% | +29.4% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.4% |
| LU, CHENG | 1 | 53.8% | +64.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18309062 | DOMINANT NEGATIVE TGFBETA RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF | GROOMS, TIFFANY NICOLE | — |
| 18308427 | IL-12 POLYPEPTIDES, IL-15 POLYPEPTIDES, IL-18 POLYPEPTIDES, CD8 POLYPEPTIDES, COMPOSITIONS, AND METHODS OF USING THEREOF | ROONEY, NORA MAUREEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18053705 | ADOPTIVE CELL THERAPY COMBINATION TREATMENT AND COMPOSITIONS THEREOF | LU, CHENG | 6d |
| 18824203 | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND METHODS THEREOF | AMICK, THOMAS RUSSE | — |
| 18309062 | DOMINANT NEGATIVE TGFBETA RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF | GROOMS, TIFFANY NICOLE | — |
| 18308427 | IL-12 POLYPEPTIDES, IL-15 POLYPEPTIDES, IL-18 POLYPEPTIDES, CD8 POLYPEPTIDES, COMPOSITIONS, AND METHODS OF USING THEREOF | ROONEY, NORA MAUREEN | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1641 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18824203 | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND METHODS THEREOF | AMICK, THOMAS RUSSE | — | Other | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18309062 | DOMINANT NEGATIVE TGFBETA RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF | GROOMS, TIFFANY NICOLE | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18308427 | IL-12 POLYPEPTIDES, IL-15 POLYPEPTIDES, IL-18 POLYPEPTIDES, CD8 POLYPEPTIDES, COMPOSITIONS, AND METHODS OF USING THEREOF | ROONEY, NORA MAUREEN | 1641 | §102§103Other | Non-Final OA | — | Pending | Apr 27, 2023 |
| 18053705 | ADOPTIVE CELL THERAPY COMBINATION TREATMENT AND COMPOSITIONS THEREOF | LU, CHENG | 1642 | §103DP | Final Rejection | 6d | Pending | Nov 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmatics US Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Thomas Russe Amick has the most, with 1 of Immatics US Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
